Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.
Bertrand N, Guerreschi P, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, Dziwniel V, Depoortère C, Duhamel A, Mortier L. Bertrand N, et al. Among authors: dalac rat s. EClinicalMedicine. 2021 Apr 26;35:100844. doi: 10.1016/j.eclinm.2021.100844. eCollection 2021 May. EClinicalMedicine. 2021. PMID: 33997740 Free PMC article.
[Stage III melanoma: Sentinel node biopsy, completion lymph node dissection and prospects of adjuvant therapy. A French national survey on current and envisaged practices].
Orion C, Dinulescu M, Dalac-Rat S, Giacchero D, Jouary T, Lebbé C, Leccia MT, Maubec E, Meyer N, Mortier L, Dupuy A; Groupe de cancérologie cutanée de la Société française de dermatologie. Orion C, et al. Ann Dermatol Venereol. 2020 Jan;147(1):9-17. doi: 10.1016/j.annder.2019.08.018. Epub 2019 Nov 21. Ann Dermatol Venereol. 2020. PMID: 31761496 French.
Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study.
Monestier S, Dalle S, Mortier L, Dutriaux C, Dalac-Rat S, Meyer N, Leccia MT, Mansard S, Montaudié H, Saiag P, Combemale P, Guillot B, Skowron F, Duval Modeste AB, Bénéton N, Hainaut E, Robert C, Arnault JP, Le Corre Y, Jouary T, Ameur N, Varey E, Khammari A, Dréno B; RIC-Mel network. Monestier S, et al. Among authors: dalac rat s. Int J Cancer. 2021 Jun 1;148(11):2789-2798. doi: 10.1002/ijc.33467. Epub 2021 Feb 19. Int J Cancer. 2021. PMID: 33428772 Free article. Clinical Trial.
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort.
Carlet C, Dalle S, Leccia MT, Mortier L, Dalac-Rat S, Dutriaux C, Legoupil D, Montaudié H, Dereure O, De Quatrebarbes J, Granel-Brocard F, Le-Bouar M, Charles J, Brunet-Possenti F, Dreno B, Lefevre W, Allayous C, Lebbe C, Nardin C. Carlet C, et al. Among authors: dalac rat s. J Am Acad Dermatol. 2022 Feb;86(2):345-352. doi: 10.1016/j.jaad.2021.06.849. Epub 2021 Jun 18. J Am Acad Dermatol. 2022. PMID: 34153388
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
Saiag P, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Dutriaux C. Saiag P, et al. Among authors: dalac rat s. Eur J Cancer. 2021 Sep;154:57-65. doi: 10.1016/j.ejca.2021.05.031. Epub 2021 Jul 6. Eur J Cancer. 2021. PMID: 34243078 Free article. Clinical Trial.
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.
Dutriaux C, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Saiag P. Dutriaux C, et al. Among authors: dalac rat s. Eur J Cancer. 2022 Nov;175:254-262. doi: 10.1016/j.ejca.2022.07.035. Epub 2022 Sep 25. Eur J Cancer. 2022. PMID: 36170791 Free article. Clinical Trial.
Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database.
L'Orphelin JM, Le Naour S, Dalle S, Varey E, Dupuy A, Montaudie H, Lesage C, Mortier L, Leccia MT, Celerier P, Skowron F, Meyer N, Maubec E, Amini-Adle M, Dalac-Rat S, Dutriaux C, Khammari A, Dompmartin A, Dreno B; RIC-Mel NETWORK. L'Orphelin JM, et al. Among authors: dalac rat s. Eur J Dermatol. 2022 Nov 1;32(6):691-697. doi: 10.1684/ejd.2022.4357. Eur J Dermatol. 2022. PMID: 36856380 English.
Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study.
Khelef K, Maubec E, Jeudy G, Bonniaud B, Pham-Ledard A, Herms F, Aubin F, Beneton N, Dinulescu M, Jannic A, Duval-Modeste A, Archier E, Berthin C, Grange F, Arnault J, Heidelberger V, Moncourier M, Mansard S, Brunet-Possenti F, Triller R, Pracht M, Dumas M, Lauche O, Mortier L, Bedane C, Dalac Rat S. Khelef K, et al. Among authors: dalac rat s. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e71-e73. doi: 10.1111/jdv.19435. Epub 2023 Sep 23. J Eur Acad Dermatol Venereol. 2024. PMID: 37595320 No abstract available.
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase).
Russo D, Dalle S, Dereure O, Mortier L, Dalac-Rat S, Dutriaux C, Leccia MT, Legoupil D, Montaudié H, Maubec E, De Quatrebarbes J, Arnault JP, Brocard FG, Saïag P, Dreno B, Allayous C, Oriano B, Lefevre W, Lebbé C, Boussemart L. Russo D, et al. Among authors: dalac rat s. Front Oncol. 2023 Oct 23;13:1250026. doi: 10.3389/fonc.2023.1250026. eCollection 2023. Front Oncol. 2023. PMID: 37936607 Free PMC article.
18 results